País: Canadà
Idioma: anglès
Font: Health Canada
IRBESARTAN; HYDROCHLOROTHIAZIDE
PHARMASCIENCE INC
C09DA04
IRBESARTAN AND DIURETICS
150MG; 12.5MG
TABLET
IRBESARTAN 150MG; HYDROCHLOROTHIAZIDE 12.5MG
ORAL
100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0240086001; AHFS:
APPROVED
2011-03-21
_pms-IRBESARTAN-HCTZ (irbesartan and hydrochlorothiazide) _ _Page 1 of 54_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-IRBESARTAN-HCTZ Irbesartan and Hydrochlorothiazide Tablets Tablets, 150 mg/12.5 mg, 300 mg/12.5 mg and 300 mg/25 mg, Oral House Standard Angiotensin II AT 1 Receptor Blocker / Diuretic PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 www.pharmascience.com Date of Initial Authorization: MAR 21, 2011 Date of Revision: APR 12, 2023 Submission Control Number: 273098 _pms-IRBESARTAN-HCTZ (irbesartan and hydrochlorothiazide) _ _Page 2 of 54_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism 06/2021 7 WARNINGS AND PRECAUTIONS, Ophthalmologic 06/2021 7 Warnings and Precautions, Respiratory 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations .................. Llegiu el document complet